Brain

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by...

Synergy CHC Corp. (NASDAQ: SNYR) Adds Five New Direct Store Delivery Partners, Expanding FOCUSfactor Functional Beverage Distribution to Ten States Nationwide

WESTBROOK, Maine, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer...

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel...

SoundHealth Launches Spatial Sleep: The World’s First Clinically Proven, Personalized, Drug-Free Wearable for Better Sleep

Proprietary acoustic sleep harmonization technology delivers tailored sound and vibration patterns based on each user’s unique craniofacial anatomy.SAN FRANCISCO--(BUSINESS WIRE)--SoundHealth,...

SoundHealth Launches Spatial Sleep: The World’s First Clinically Proven, Personalized, Drug-Free Wearable for Better Sleep

Proprietary acoustic sleep harmonization technology delivers tailored sound and vibration patterns based on each user’s unique craniofacial anatomy.SAN FRANCISCO--(BUSINESS WIRE)--SoundHealth,...

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage...

Compassion Center, the Las Vegas Community, and Loved Ones Honor the Life and Immeasurable Legacy of Julie “Nurse Juhlzie” Monteiro with Community Celebrations December 13-14, 2025

error: Content is protected !!